Arthritis

FILE - In this July 6, 2020 file photo, a health care worker administers a COVID-19 test at a site sponsored by Community Heath of South Florida at the Martin Luther King, Jr. Clinica Campesina Health Center in Homestead, Fla. A drug company says on Friday, Sept. 18, that a medicine it sells to tamp down inflammation has helped prevent the need for breathing machines in hospitalized COVID-19 patients in the first large study that primarily enrolled minorities. (AP Photo/Lynne Sladky, File)
September 18, 2020 - 11:37 am
A drug company said Friday that a medicine it sells to tamp down inflammation has helped prevent the need for breathing machines in hospitalized COVID-19 patients in the first large study that primarily enrolled Hispanics and Blacks. Switzerland-based Roche reported the results for tocilizumab,...
Read More
This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the virus that causes COVID-19. The sample was isolated from a patient in the U.S. (NIAID-RML via AP)
March 19, 2020 - 4:51 pm
President Donald Trump focused attention on possible treatments for the new coronavirus on Thursday, citing potential use of a drug long used to treat malaria and some other approaches still in testing. At a White House news conference, Trump and Food and Drug Administration Commissioner Dr...
Read More
March 10, 2018 - 11:51 am
NEW YORK (AP) — An aging kangaroo who calls the Bronx Zoo home is receiving low-temperature cryotherapy treatment for arthritis. The treatment is a high-tech alternative to ice baths that humans have used for years. Zoo director Jim Breheny tells the Daily News that the nearly 15-year-old marsupial...
Read More
In this Wednesday, Nov. 15, 2017, photo, Brad Sippy, chief executive officer of Tremeau Pharmaceuticals, Inc., stands for a portrait in Cambridge, Mass. Tremeau Pharmaceuticals, Inc., is a small startup trying to bring the recalled painkiller Vioxx back to the market. They are seeking FDA approval for patients with hemophilia with severe pain, but once on the market, doctors could go back to prescribing it to anyone with pain. (AP Photo/Steven Senne)
November 21, 2017 - 10:42 am
TRENTON, N.J. (AP) — The Latest on the possible return of Vioxx (all times local): 10:30 a.m. Could the once-popular arthritis pill Vioxx (VEYE-ochs) get a second life? A startup pharmaceutical company hopes so. In 2004, Merck & Co. voluntarily pulled the blockbuster drug amid evidence it...
Read More
In this Wednesday, Nov. 15, 2017, photo, Brad Sippy, chief executive officer of Tremeau Pharmaceuticals, Inc., stands for a portrait in Cambridge, Mass. Tremeau Pharmaceuticals, Inc., is a small startup trying to bring the recalled painkiller Vioxx back to the market. They are seeking FDA approval for patients with hemophilia with severe pain, but once on the market, doctors could go back to prescribing it to anyone with pain. (AP Photo/Steven Senne)
November 21, 2017 - 6:12 am
TRENTON, N.J. (AP) — Could there be a second life for the once-popular arthritis pill Vioxx? A startup pharmaceutical company hopes so. Merck & Co. voluntarily pulled the blockbuster drug in 2004 amid evidence that it doubled the chances of having a heart attack or stroke. Now tiny Tremeau...
Read More
FILE - In this July 16, 2012 file photo, Johnson & Johnson products are displayed in Orlando, Fla. Johnson & Johnson reports earnings, Tuesday, Oct. 17, 2017. (AP Photo/John Raoux, File)
October 17, 2017 - 8:39 am
Higher spending across the board drove Johnson & Johnson's third-quarter profit down 12 percent, despite a big sales jump fueled by recent acquisitions, hot new cancer drugs and strong sales of other key medicines. However, the health care giant easily topped Wall Street expectations. With...
Read More
King Michael Odunayo Ajayi, right, of Nigeria's Osun state, is escorted by Jim Byrne, New York Stock Exchange head of U.S. listings, as he visits the trading floor of the NYSE, Monday, April 17, 2017. (AP Photo/Richard Drew)
April 17, 2017 - 4:28 pm
NEW YORK (AP) — U.S. stocks bounced back from recent losses Monday after the Chinese government said that country's economy grew at a slightly faster pace in the first quarter. Banks jumped as interest rates recovered. After losses in three of the last four weeks, stocks had their best day in more...
Read More
King Michael Odunayo Ajayi, right, of Nigeria's Osun state, is escorted by Jim Byrne, New York Stock Exchange head of U.S. listings, as he visits the trading floor of the NYSE, Monday, April 17, 2017. (AP Photo/Richard Drew)
April 17, 2017 - 11:27 am
NEW YORK (AP) — U.S. stocks are starting higher Monday as investors get back to trading after the Easter holiday weekend. Technology companies are making some of the largest gains and industrial and consumer-focused companies are also rising after the Chinese government said that country's economy...
Read More
Heidi Wyandt, 27, puts on her coat to leave the Altoona Center for Clinical Research in Altoona, Pa., on Wednesday, March 29, 2017, where she is helping test an experimental non-opioid pain medication for chronic back pain related to a work related injury she received in 2014. With about 2 million Americans hooked on opioid painkillers, researchers and drug companies are searching for less addictive drugs to treat pain. (AP Photo/Chris Post)
April 17, 2017 - 1:30 am
Tummy tucks really hurt. Doctors carve from hip to hip, slicing off skin, tightening muscles, tugging at innards. Patients often need strong painkillers for days or even weeks, but Mary Hernandez went home on just over-the-counter ibuprofen. The reason may be the yellowish goo smeared on her 18-...
Read More
FILE - This Thursday, June 30, 2011, file photo shows a sign in front of the Eli Lilly and Company corporate headquarters in Indianapolis. On Friday, April 14, 2017, Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker's second drug development setback since November 2016. (AP Photo/Darron Cummings, File)
April 14, 2017 - 12:34 pm
Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker's second drug development setback since November. The Food and Drug Administration said in a letter to the company that it needed more information about the drug's...
Read More

Pages